Status:
COMPLETED
A Study of Ultra High Dose Diuretics to Treat Heart Failure
Lead Sponsor:
Mayo Clinic
Conditions:
Heart Failure; With Decompensation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.
Eligibility Criteria
Inclusion
- Diagnosis of decompensated heart failure receiving intravenous diuretics
- Ability to provide informed consent
Exclusion
- Patients on home inotrope medications
- Patients with Chronic Kidney disease stage V and end stage renal failure on dialysis
- Patients lacking the capacity to consent for themselves
- Known pregnancy or breastfeeding mothers
- Complex congenital heart disease
- Allergy to furosemide or bumetanide
- Respiratory failure requiring non-invasive ventilation (CPAP/BiPAP) or invasive mechanical ventilatory support at the time of randomization
- Hypotension with systolic blood pressure \<80 mm Hg at the time of randomization
- Acute coronary syndrome
- Sustained Ventricular tachycardia requiring treatment in the last 48 hours
- Patients weighing ≤ 40 kg
Key Trial Info
Start Date :
November 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 8 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06036914
Start Date
November 27 2023
End Date
October 8 2024
Last Update
December 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905